{"id":7788,"date":"2026-04-29T08:00:00","date_gmt":"2026-04-29T06:00:00","guid":{"rendered":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-mars-2026\/"},"modified":"2026-04-29T08:00:00","modified_gmt":"2026-04-29T06:00:00","slug":"nanexa-publicerar-delarsrapport-for-januari-mars-2026","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-mars-2026\/","title":{"rendered":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-mars 2026"},"content":{"rendered":"<div class=\"mfn-preamble\">\n<p><strong>\u00d6ppnade \u00e5ret med starka prekliniska resultat f\u00f6r enm\u00e5nads och kvartalsvis dosering av semaglutid<\/strong><\/p>\n<\/div>\n<div class=\"mfn-body\">\n<p>V\u00e4sentliga h\u00e4ndelser under f\u00f6rsta kvartalet 2026<\/p>\n<ul>\n<li>Nanexa presenterade i januari banbrytande prekliniska data som visade en exceptionell farmakokinetisk profil f\u00f6r m\u00e5nadsdosering av semaglutid.<\/li>\n<li>Nanexa meddelade i februari att valberedningen inf\u00f6r \u00e5rsst\u00e4mma 2026 utsetts. Valberedningens ledam\u00f6ter utg\u00f6rs av Marlon V\u00e4rnik, Jonas P\u00e5lsson och G\u00f6ran Ando.<\/li>\n<li>Nanexa visade i mars utm\u00e4rkta resultat f\u00f6r en trem\u00e5nadersdosering av semaglutid.<\/li>\n<\/ul>\n<p>V\u00e4sentliga h\u00e4ndelser efter periodens utg\u00e5ng<\/p>\n<ul>\n<li>Nanexa informerade i april att samtliga teckningsoptioner som emitterades under v\u00e5ren 2025 hade nyttjats f\u00f6r teckning av aktier. Genom nyttjandet av teckningsoptionerna tillf\u00f6rdes Nanexa totalt 55,7 MSEK f\u00f6re emissionskostnader.<\/li>\n<li>Nanexa meddelade den 28 april att styrelsen, med st\u00f6d av bemyndigande fr\u00e5n bolagsst\u00e4mman den 15 maj 2025, beslutat om en nyemission av aktier d\u00e4r betalning sker genom kvittning av hela det utest\u00e5ende l\u00e5net om totalt 20 MSEK.<\/li>\n<\/ul>\n<p><\/p>\n<p>Finansiell \u00f6versikt<\/p>\n<p>1 januari &#8211; 31 mars 2026<\/p>\n<ul>\n<li>Oms\u00e4ttningen uppgick till: 1 632 (2 877) kSEK<\/li>\n<li>R\u00f6relseresultatet (EBIT) uppgick till: -13 610 (-8 213) kSEK<\/li>\n<li>Periodens resultat uppgick till: -14 023 (-8 987) kSEK<\/li>\n<li>Resultat per aktie uppgick till: -0,08 (-0,06) SEK<\/li>\n<li>Periodens kassafl\u00f6de uppgick till: 28 455 (38 924) kSEK<\/li>\n<li>Likvida medel vid periodens utg\u00e5ng: 73 022 (49 216) kSEK<\/li>\n<\/ul>\n<p><em>Siffror inom parentes avser motsvarande period f\u00f6reg\u00e5ende \u00e5r.<\/em><\/p>\n<p>Rapporten i sin helhet finns tillg\u00e4nglig p\u00e5 bolagets hemsida: <a href=\"https:\/\/nanexa.com\/finansiella-rapporter\/\" rel=\"noopener\" target=\"_blank\">https:\/\/nanexa.com\/finansiella-rapporter\/<\/a>.<\/p>\n<p>Rapportkommentar 29 april kl 10:00<\/p>\n<p>En lives\u00e4nd kommentar med vd David Westberg h\u00e5lls den 29 april kl 10:00 via Infront Direkt Studios och tittarna ges m\u00f6jlighet att st\u00e4lla fr\u00e5gor via chat.<\/p>\n<p>Rapportkommentaren kommer att finnas tillg\u00e4nglig via <a href=\"https:\/\/eur01.safelinks.protection.outlook.com\/?url=https%3A%2F%2Fwww.youtube.com%2Fwatch%3Fv%3Dp9dWW4Lje9c&amp;data=05|02|ulrika.parlefors%40nanexa.se|1d53ef6ba4cc41cce71608de9b3d29ca|cf2057b571ae407dac1e06fc7f9e6904|0|0|639118884180724331|Unknown|TWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D|0|||&amp;sdata=j5jy0%2BFnJ2PbUNbBhWLL3mFbvSPGKCV6%2BlHOOhfxBqM%3D&amp;reserved=0\" rel=\"noopener\" target=\"_blank\">denna l\u00e4nk<\/a><\/p>\n<p>Rapportkommentaren kommer \u00e4ven att l\u00e4ggas upp p\u00e5 Nanexas hemsida i efterhand.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-contacts mfn-2376405b3437\">\n<p><strong class=\"mfn-heading-1\">F\u00f6r mer information kontakta:<\/strong><\/p>\n<hr \/>\n<p>David Westberg \u2013 vd, Nanexa AB (publ)\u00a0<br \/>Telefon: 0709-42 83 03<br \/>E-post:\u00a0<a href=\"mailto:david.westberg@nanexa.se\" rel=\"noopener\" target=\"_blank\">david.westberg@nanexa.se<\/a><br \/><a href=\"http:\/\/www.nanexa.com\" rel=\"noopener\" target=\"_blank\">www.nanexa.com<\/a><\/p>\n<p>Bolagets Certified Adviser \u00e4r Tapper Partners AB.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-about mfn-c9ba281e2dde\">\n<p><strong class=\"mfn-heading-1\">Om Nanexa AB (publ)<\/strong><\/p>\n<hr \/>\n<p>Nanexa introducerar kontroll, precision och m\u00e5ngsidighet till l\u00e4kemedelsformuleringar med hj\u00e4lp av ALD-teknik (Atomic Layer Deposition). F\u00f6retagets patenterade PharmaShell\u00ae-plattform \u00e4r ett unikt drug delivery-system som m\u00f6jligg\u00f6r h\u00f6g drug load vilket ger l\u00e5g injektionsvolym och skapar en ny generation formuleringar, s\u00e5 kallade \u201dsuper generics\u201d som ger st\u00f6rre bekv\u00e4mlighet och minskar kostnaderna vid behandling av allehanda sjukdomstillst\u00e5nd som metabola sjukdomar, t ex typ 2-diabetes och obesitas, hematologi\/onkologi, hj\u00e4rt-k\u00e4rlsjukdomar, psykiatri och m\u00e5nga andra.<br \/>Nanexa utvecklar egna l\u00e4kemedelsprodukter och har dessutom samarbetsavtal med flera l\u00e4kemedelsbolag, d\u00e4ribland det senaste licens- och optionsavtalet med Moderna.<\/p>\n<p>Nanexas aktie \u00e4r noterad p\u00e5 Nasdaq First North Growth Market i Stockholm (NANEXA).<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-regulatory mfn-regulatory-mar\">\n<p><em>Denna information \u00e4r s\u00e5dan information som Nanexa \u00e4r skyldigt att offentligg\u00f6ra enligt EU:s marknadsmissbruksf\u00f6rordning. Informationen l\u00e4mnades, genom ovanst\u00e5ende kontaktpersoners f\u00f6rsorg, f\u00f6r offentligg\u00f6rande den 2026-04-29 08:00 CEST.<\/em><\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr \/>\n<p><a class=\"mfn-primary\" href=\"https:\/\/storage.mfn.se\/8b058213-aa90-4a9f-adfd-a42dd11a05cd\/nanexa-delarsrapport-januari-mars-2026.pdf\" rel=\"noopener\" target=\"_blank\">Nanexa Del\u00e5rsrapport Januari Mars 2026<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u00d6ppnade \u00e5ret med starka prekliniska resultat f\u00f6r enm\u00e5nads och kvartalsvis dosering av semaglutid<\/p>\n","protected":false},"template":"","class_list":["post-7788","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-report-interim_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn-regulatory-mar_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-report-interim-q1_sv","mfn-news-tag-mfn-report_sv","mfn-news-tag-mfn-regulatory_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-mars 2026 - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-mars-2026\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-mars 2026 - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"\u00d6ppnade \u00e5ret med starka prekliniska resultat f\u00f6r enm\u00e5nads och kvartalsvis dosering av semaglutid\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-mars-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-mars-2026\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-mars-2026\\\/\",\"name\":\"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-mars 2026 - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2026-04-29T06:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-mars-2026\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/sv\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-mars-2026\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-mars-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-mars 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-mars 2026 - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-mars-2026\/","og_locale":"sv_SE","og_type":"article","og_title":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-mars 2026 - Nanexa AB","og_description":"\u00d6ppnade \u00e5ret med starka prekliniska resultat f\u00f6r enm\u00e5nads och kvartalsvis dosering av semaglutid","og_url":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-mars-2026\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-mars-2026\/","url":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-mars-2026\/","name":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-mars 2026 - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2026-04-29T06:00:00+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-mars-2026\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-mars-2026\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-mars-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-mars 2026"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/7788","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=7788"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}